You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,892,542


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,892,542
Title:Human anti-idiotypic antibody fragments that mimic HER-2/neu
Abstract: This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.
Inventor(s): Gauthier; Philippe (Grabels, FR), Pelegrin; Andre (Montpellier, FR), Coelho; Mickael (Montpellier, FR), Teulon; Isabelle (Saint Gely du Fesc, FR)
Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR) Centre Regional de Lutte Contre le Cancer \"Val d\'Aurelle-Paul Lamarque\" (Montpellier Cedex, FR) Universite Montpellier I (Montpellier Cedex, FR)
Application Number:10/583,034
Patent Claims:1. An isolated human anti-idiotypic antibody Fab- or scFv-fragment, which mimics Her-2/neu tumor associated antigen, and which comprises CDR1H, CDR1L, CDR2H, CDR2L, CDR3H and CDR3L, wherein the amino acid sequence of CDR1H consists of the sequence SYAMS (SEQ ID No: 15), wherein the amino acid sequence of CDR1L consists of the sequence QGDSLRSYYAS (SEQ ID No: 16), wherein the amino acid sequence of CDR2H consists of the sequence SGGTYYADSVKG (SEQ ID No: 17), wherein the amino acid sequence of CDR2L consists of the sequence GKNNRPS (SEQ ID No: 18), and (i) wherein the amino acid sequence of CDR3H consists of the sequence SEQ ID No: 3 when the amino acid sequence of CDR3L consists of the sequence SEQ ID No: 4, or (ii) wherein the amino acid sequence of CDR3H consists of the sequence SEQ ID No: 5 when the amino acid sequence of CDR3L consists of the sequence SEQ ID No: 6, wherein said fragment binds trastuzumab F(ab').sub.2.

2. The fragment of claim 1, wherein CDR3H consists of SEQ ID No: 3 and CDR3L consists of SEQ ID No: 4.

3. The fragment of claim 2, which comprises the amino acid sequence SEQ ID No: 1, this fragment being designated scFv40.

4. The fragment of claim 1, wherein CDR3H consists of SEQ ID No: 5 and CDR3L consists of SEQ ID No: 6.

5. The fragment of claim 4, which comprises the amino acid sequence SEQ ID No: 2, this fragment being designated scFv69.

6. A multimer of the antibody fragment defined in claim 1.

7. A pharmaceutical composition comprising an antibody fragment according to claim 1, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

8. An isolated human anti-idiotypic antibody Fab- or ScFv-fragment, which mimics Her-2/neu tumor associated antigen, wherein said fragment comprises the amino acid sequence SEQ ID No: 1, this fragment being designated scFv40, wherein said fragment binds to trastuzumab F(ab').sub.2.

9. A multimer of the antibody fragment defined in claim 8.

10. A pharmaceutical composition comprising an antibody fragment according to claim 8, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

11. An isolated human anti-idiotypic antibody Fab- or ScFv-fragment, which mimics Her-2/neu tumor associated antigen, wherein said fragment comprises the amino acid sequence SEQ ID No: 2, this fragment being designated scFv69, wherein said fragment binds to trastuzumab F(ab').sub.2.

12. A multimer of the antibody fragment defined in claim 11.

13. A pharmaceutical composition comprising an antibody fragment according to claim 11, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

Details for Patent 7,892,542

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2023-12-17
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2023-12-17
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2023-12-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.